|Bid||0.0000 x 800|
|Ask||0.0000 x 3000|
|Day's Range||1.1800 - 1.2699|
|52 Week Range||0.7600 - 10.8000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pain Therapeutics Inc. said Wednesday it's changing its name and ticker to better reflect its focus on developing drugs for neurodegenerative diseases such as Alzheimer's. The company will be named Cassava Sciences Inc. with immediate effect. From March 28, it will start trading on Nasdaq under the new ticker symbol "SAVA." The company is currently in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that does not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. It is also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test. Shares rose 1.7% in premarket trade, but have fallen 82.2% in the last 12 months, while the S&P 500 has gained 7.9%.
If you own shares in Pain Therapeutics, Inc. (NASDAQ:PTIE) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Back to Brussels, May Says No Support for Second Brexit Referendum British Prime Minister Theresa May, who somehow is still the Prime Minister of the United Kingdom despite being defeated in almost every critical legislative vote surrounding Brexit which she was brought aboard to deliver, is going back to Brussels to renegotiate the Irish backstop, […] The post Market Update: May Back to Brussels, BP Gushes Oil, Iron Spike, Pain Feels Pain appeared first on Market Exclusive.
Every investor in Pain Therapeutics Inc (NASDAQ:PTIE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
shed 53% to $1.35 on Thursday, Oct. 4, after the company said it was filing an "administrative appeal" with the Federal Drug Administration after the agency rejected a drug the company was developing. In August, the FDA rejected Pain Therapeutics' Remoxy drug, an oxycodone designed to discourage most methods of tampering linked to opioid abuse, because the benefits of the drug weren't great enough to justify the risks. The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, part of the FDA, voted 14 to 3 against the drug.
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
Pain Therapeutics notes that the grant is for a total of $3.20 million. PTI-125 is a new drug that Pain Therapeutics is developing to treat Alzheimer’s disease. The drug is a molecule that has the potential to treat Alzheimer’s disease.
The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement. Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.
Pain Therapeutics said on Monday that the U.S. Food and Drug Administration declined to approve its opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," said Chief Executive Officer Remi Barbier said in a statement. The FDA's "complete response letter" marks the latest setback to the U.S. drug developer and the treatment, Remoxy ER, which has failed to get marketing approval on the past three attempts.
Earnings is providing a much-needed boost to the biotech sector last week, with big-name companies like Eli Lilly And Co (NYSE: LLY ) and Pfizer Inc. (NYSE: PFE ) all trading at fresh 52-week highs in ...
Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is up about 5 percent. As the earnings season kicks ...
This week was a rough one for biotech company Pain Therapeutics, Inc. (NASDAQ:PTIE) after the firm’s pain drug, Remoxy ER, was shot down by the FDA advisory committee. PTIE stock had been trading at more than $9 per share ahead of the news and investors were hopeful about the drug’s potential. The biotech space is a risky one because FDA approval weighs so heavily on companies’ success.
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
Biotech stocks saw some upward momentum last week. The defensive nature of biotech stocks drove investors into the space amid a rise in risk aversion following the ongoing U.S.-China trade war. The week ...
The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved ...